Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Clalit Health Services

Status and phase: Completed; Phase 4

Conditions: Bronchoscopy

Treatments: Drug: Labetalol 10mg iv

Study type: Interventional

Funder types: Other

Identifiers

NCT00394537

3997

Details and patient eligibility

About

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.

We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Enrollment: 72 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion criteria

• inability or refusal to give informed consent
• bronchoscopy through an artificial airway
• intolerance or allergy to the study drug
• bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
• pregnancy,
• concomitant treatment with diltiazem or verapamil
• intention to use propofol as the sedative agent for bronchoscopy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind